文献速递脑血管病

ENTF神经调控减少卒中后残疾:个体参与者数据荟萃分析

ENTF Neuromodulation Yields Reduced Disability After Stroke: An Individual Participant-Level Data Meta-Analysis.
PubMed 文献 · Stroke · 2026-07-01

该研究汇总2项双盲随机假刺激对照试验的个体数据,纳入124例亚急性缺血性卒中伴中重度残疾患者。结果显示,与假刺激相比,ENTF治疗组在8-12周时无残疾(mRS 0-1)比例更高(33.8% vs 11.9%,P=0.005),且残疾改善更优,安全性良好。

要点

  • ENTF治疗可提高亚急性缺血性卒中患者8-12周无残疾比例。
  • ENTF组残疾等级分布及改善程度均优于假刺激组。
  • 未观察到设备或操作相关的严重不良事件。

核心结论

  • 在2项随机假刺激对照试验的汇总数据中,ENTF治疗较假刺激可提高亚急性缺血性卒中伴中重度残疾患者的无残疾率、改善残疾程度并降低最终残疾水平。

研究设计与样本

  • 汇总2项双盲随机假刺激对照试验(BQ3和EMAGINE 1)的个体患者数据,共纳入124例患者(活性组65例,假刺激组59例)。

主要发现

  • 8-12周时,活性ENTF组无残疾(mRS 0-1)比例为33.8%,假刺激组为11.9%(P=0.005)。
  • 在3个残疾分层(mRS 0-1、2、>2)的序贯移位分析中,结果亦 favoring ENTF(P=0.009)。
  • 聚焦上肢运动终点非显著性地 favoring ENTF。
  • 安全性分析显示无设备或操作相关的严重不良事件。

关键数值与推荐

  • 关键入组标准:缺血性卒中后4-21天,Fugl-Meyer上肢评分10-45分;EMAGINE 1额外要求入组mRS 3-4分。
  • 主要结局:8-12周无残疾(mRS 0-1)。

临床怎么用

  • 对于亚急性缺血性卒中伴中重度残疾(mRS 3-4)且上肢运动功能部分保留(FMA-UE 10-45)的患者,ENTF可作为促进恢复、减少残疾的潜在治疗选择。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Electromagnetic network-targeted field (ENTF) brain stimulation therapy is a promising approach to reduce poststroke disability. Two pilot, randomized, sham-controlled trials showed safety and signals of efficacy. The aim of this study was to perform a pooled analysis with greater statistical power to characterize with precision the effect of ENTF in promoting recovery and reducing disability. METHODS: We pooled individual patient-level data from 2 double-blind, randomized, sham-controlled studies, BQ3 (BrainQ3 Trial; Unique identifier: NCT04039178) and EMAGINE 1 (Electromagnetic Field Ischemic Stroke-Novel Subacute Treatment Trial; NCT05044507). Key entry criteria in both trials were (1) 4 to 21 days post-ischemic stroke and (2) Fugl-Meyer assessment-upper extremity score of 10 to 45. For EMAGINE 1, an additional criterion was a study entry modified Rankin Scale (mRS) score of 3 to 4. The primary outcome for this pooled analysis was freedom-from-disability (mRS score, 0-1) at 8 to 12 weeks. Secondary outcomes were level of disability (ordinal mRS score distribution), disability change (delta mRS score) change from entry to 8 to 12 weeks, and 2 focused upper extremity motor end points. RESULTS: Altogether, 124 patients were included (active n=65; sham n=59). The mean age was 58.2±13.1 years, 31% were female, the study entry Fugl-Meyer assessment-upper extremity score was 25.3 (±10.6), and the therapy started 14.5 (±4.9) days poststroke. The study entry mRS score was 3.9 (±0.36), and 123/124 (99.2%) had a study entry mRS score of 3 to 4. Study entry features were well-balanced across treatment groups. At 8 to 12 weeks, freedom-from-disability was higher with active ENTF than sham stimulation (33.8% versus 11.9%; P=0.005). Ordinal shift across 3 disability strata (mRS score, 0-1, 2, and >2) also favored ENTF (P=0.009). Focused upper extremity motor end points nonsignificantly favored ENTF. Safety analyses showed no device- or procedure-related serious adverse events. CONCLUSIONS: In pooled data from 2 randomized, sham-controlled trials, treatment with ENTF compared with sham for patients with subacute ischemic stroke with moderate-severe study entry disability yielded increased achieved freedom-from-disability, greater disability improvement from study entry, and reduced final disability level. These findings, together with an attractive safety profile, support ENTF as a promising therapy for stroke recovery.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Saver JL, Stein J, Cramer SC, et al. ENTF Neuromodulation Yields Reduced Disability After Stroke: An Individual Participant-Level Data Meta-Analysis. Stroke. 2026. PMID: 42381628. doi:10.1161/STROKEAHA.125.054959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。